Genovis AB: Genovis and Glykos partner to enable new ADC platform

By using GlyCLICK®, a site-specific antibody conjugationtechnology from Genovis and the latest novel linker and cytotoxic drug derivatives from Glykos,Genovis will offer biopharma customers a platform to screen and develop Antibody Drug Conjugates (ADCs) with improved performance. The partnership between Genovis and Glykos will enable scientists around the world to build ADCs from any off-the-shelf antibody, resulting in highly defined end products.

• With Glykos unique linker and payload technologies, we can now offer the biopharma community a platform to rapidly transform any antibody into an advanced site-specific antibody drug conjugate. This enables our customers to explore new ways to develop ADCs which further broaden our market offering, says Fredrik Olsson CEO of Genovis.

• With Genovis industry leading antibody processing enzymes and the GlyCLICK® platform, collaboration with Genovis opens new user base to our linker-payload ADC technologies. The combined product enables scientists to efficiently generate ADCs from their pipeline antibodies and to assess their functionality as unique research tools and potential therapeutics, says Juhani Saarinen CEO of Glykos.

The new GlyCLICK ADC products are available for purchase globally today through Genovis and distributors. For more information visit: https://www.genovis.com/applications/adc-development/

More about ADC

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating primarily cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.

More about GlyCLICK®

The antibody conjugation technology GlyCLICK continues to show steady uptake in a range of markets and applications. One such application is the generation of site-specific antibody drug conjugates with defined number of drug molecules per antibody. The GlyCLICK technology encompasses enzymatic remodeling of the Fc-glycans and click-chemistry to ensure site-specific conjugation of antibodies.

About Glykos

Glykos’ business concept is to apply its technologies to provide state-of-the-art ADCs for clinical development. Today Glykos collaborates with pharmaceutical industry clients to advance novel ADCs towards the clinic. Glykos ADC technology platform includes glycoconjugation, stabilized maleimide conjugation, hydrophilic linkers for enhanced pharmacokinetics and novel high-potency payloads with improved therapeutic index. Glykos provides a full technology platform that enables development of superior ADC products in a very short development timeframe. For more information visit www.glykos.fi.